Following the US midterm elections, Arizona Senator Mark Kelly used day one of HLTH 2026 in Las Vegas to set out the Democrats’ emerging healthcare priorities, against a backdrop of mounting frustration over the cost and accessibility of US healthcare.

Affordability dominated the discussion, with a clear message for pharma: drugmakers will face greater scrutiny as Democrats look to rein in healthcare costs.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Kelly, a former astronaut and potential 2028 presidential contender, called US healthcare “a disaster for millions and millions of Americans”.

Sharing the stage with Shaughnessy Naughton, founder of pro-science political group 314 Action, Kelly outlined a two-stage plan for the new Congress, which convenes on January 3. First, halt coverage losses under Medicaid and restore enhanced Affordable Care Act (ACA) subsidies. Then turn to longer-term reforms.

A warning for pharma

Kelly’s message to drugmakers was pointed: hospitals, insurers and pharmaceutical companies “often make very big profits”, he said. “We need to fix that part of it as well.”

The Democrats’ immediate priorities, Kelly said, are to protect Medicaid coverage and restore enhanced ACA tax credits. He criticised Republican tax legislation for helping fund tax cuts through cuts to Medicaid and food assistance, arguing that the new Congress must first address the resulting gaps in coverage before turning to broader healthcare reform.

To illustrate the pressure on patients, he cited a mother of three in Yuma, Arizona, whose monthly ACA premium had risen from $560 to $3,000. Families facing such increases, he suggested, would simply drop coverage.

For drugmakers, this presents a familiar tension. More insured patients means greater access to medicines and fewer people unable to fill prescriptions. But Democrats are linking expanded coverage to a broader challenge over healthcare prices and industry profits.

On longer-term reform, Kelly left the door open to more radical options. Asked about proposals to expand Medicare eligibility or introduce Medicare for All, he said: “I wouldn’t rule anything out.” He stopped short of endorsing a particular model, but stressed that healthcare “shouldn’t cost this much”.

For pharma, the implications are significant. Any expansion of Medicare could bring more patients under government pricing rules, reinforcing the link between Democrats’ ambitions to widen coverage and their push to lower healthcare costs.

China, research and regulation

Biotech prompted the sharpest industry-specific exchange. Public health physician Vin Gupta highlighted China’s growing share of pharmaceutical licensing deals, underlining the country’s expanding influence in global drug development.

Kelly described China’s biotechnology push as “aggressive” and “on a scale that we haven’t seen before”. But he stopped short of calling for restrictions on Chinese assets, arguing that Americans should have access to “the best medicine available”, wherever it originates.

Instead, he called for greater domestic manufacturing and more resilient supply chains. Naughton emphasised the need for renewed investment in basic research, which she said had suffered under the current administration, and FDA reform to encourage more clinical trials to take place in the US.

“We are ceding our role to China,” she warned.

Both speakers backed stronger protections for research funding. Kelly proposed preventing grants from being cancelled midway through studies, while Naughton highlighted the Scientific Integrity Act, which aims to shield research decisions from political interference.

Artificial intelligence (AI) regulation was another priority. Kelly pointed to his white paper, AI for America, as the basis for forthcoming legislation, arguing that Congress must play a central role in setting the rules while recognising AI’s potential in healthcare.

Three messages emerged: affordability will bring drug pricing into the debate; China policy will focus on domestic research and manufacturing rather than blocking licensing deals; and scientific funding and regulatory independence are becoming political priorities.

But this was a statement of intent, not a legislative programme. President Trump has threatened vetoes, and Kelly acknowledged the difficulty of reversing Republican tax legislation.

For now, pharma has a warning, not a roadmap: Democrats want more Americans covered, but they also want the industry to explain what it charges.